

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 27, 2023

**INMUNE BIO INC.**

(Exact name of registrant as specified in charter)

**Nevada**

(State or other jurisdiction  
of incorporation)

**001-38793**

(Commission File Number)

**47-5205835**

(IRS Employer  
Identification No.)

**225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432**

(Address of Principal Executive Offices) (Zip Code)

**(858) 964 3720**

(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.001 per shares	INMB	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ?

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?

**Item 8.01. Other Events.**

On November 27, 2023, INmune Bio Inc. (the “Company”), issued a press release announcing that the Company has received European Medicines Agency’s Authorized Decision from the Agence Nationale de Securite du Medicament et des Produits de Sante in France and the Agencia Espanola de Medicamentos y Productos Sanitarios in Spain to initiate a Phase II trial in Early Alzheimer’s Disease (AD) with XPro™.

A copy of the press release is attached herewith as Exhibit 99.1.

#### Item 9.01 Financial statements and Exhibits

(d) Exhibits.

99.1	<a href="#">Press Release dated November 27, 2023</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INMUNE BIO INC.**

Date: November 27, 2023

By: /s/ David Moss

David Moss  
Chief Financial Officer